An interventional study of Angiography-guided PCI group and Optical coherence tomography-guided PCI group in ST Elevation Myocardial Infarction and Myocardial Infarction, sponsored by Chonnam National University Hospital. Recruiting at 18 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of — 8 open to participants now, 12 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · Korea, Republic of.
Among the 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of, this one is the 5th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2024, is one of 14 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 30th registered.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →8 of the 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Gyeongsang National University Hospital · Sites in Korea, Republic of
Ages 19+
Chungnam National University Hospital · Sites in Korea, Republic of
Ages 20+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 314 across the 28 interventional studies, 1,467 across the 8 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
Chonnam National University Hospital is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
Chonnam National University Hospital has 3 studies filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
2 of the studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT07947498Chungnam National University HospitalPrognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial Infarction | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).
Percutaneous coronary intervention (PCI) is a standard treatment for significantly stenotic lesion of coronary arteries, especially in the setting of acute myocardial infarction (AMI) where timely reperfusion is important. Traditionally, visual assessment by coronary angiography has been the main tool to identify coronary artery disease and guide revascularization. However, it is known that angiography alone is unable to adequately evaluate significance of stenotic lesion or optimization status of the stent, and that angiography suffers from high intra- and interobserver variability. Thus, methods for intracoronary imaging and/or physiology have been developed to aid these limitations.
During the PCI procedure, intravascular imaging devices such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are useful tools for providing information on lesion characteristics and optimal stent implantation with regard to appropriate reference segment, stent expansion, stent apposition, and possible acute complications. Therefore, intravascular imaging guidance may improve clinical outcomes after complex PCI. However, although previous randomized controlled trial and registries showed significantly lower rates of major adverse clinical events following IVUS-guided PCI compared with angiography-guided PCI, the randomized controlled trials were limited with small sample size and dealt with very selected lesion subsets such as chronic total occlusion (CTO) or long lesions. Moreover, although some studies observed similar clinical outcomes between IVUS-guided PCI and OCT-guided PCI, it is uncertain whether OCT-guided PCI improves clinical outcomes compared with angiography-guided PCI.
Currently, randomized controlled trial to support beneficial impact of OCT-guided PCI, especially in patients with acute myocardial infarction (AMI) is lacking. One randomized clinical trial in 2016 with 240 non-ST-elevation myocardial infarction patients have reported higher postprocedural fractional flow reserve and similar incidence of major adverse cardiac events with the use of OCT compared to angiography alone, but this study mostly focused on immediate physiologic findings of OCT-guided PCI and only demonstrated clinical outcomes on short-term follow-up. Although the ILUMIEN IV trial evaluated efficacy of OCT-guided PCI among high risk patients including lesions were considered to be responsible for a recent myocardial infarction, there was no apparent difference in the target-vessel failure at 2 years. There is no randomized controlled trial that can provide information on its long-term clinical impact, and current clinical guidelines puts OCT on Class 2a recommendation as an alternative for IVUS, with the exception of ostial left main disease.
In this regard, randomized controlled trial comparing clinical outcome following PCI in patients with AMI where procedural optimization is performed under OCT-guidance or angiography alone would provide valuable evidence to enhance prognosis after treatment of AMI. Therefore, FRAME-AMI 3 trial has been designed to compare clinical outcomes after PCI for infarct-related artery using either OCT-guided or angiography-guided strategy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Acute ST-segment elevation myocardial infarction (STEMI)
*STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block1
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The PCI procedure in this group will be performed as standard procedure.
Procedure: Angiography-guided PCI group
Use of OCT will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but OCT after stent implantation will be mandatory. In this group, the recommendations for selecting reference segment, selecting appropriate size of stent, and stent optimization are as follows. OPTIS imaging catheter (Abbott Vascular) will be used for the imaging arm according to MLD MAX algorithm.
Procedure: Optical coherence tomography-guided PCI group
The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.
\[Stent Optimization\] 1. Stent Expansion: Visually assess residual angiographic diameter stenosis \<10% "AND" ① In non-LM lesions: In-stent minimal lumen area (MSA) \>80% of the average reference lumen area "OR" \>4.5 mm2 ② In LM lesion: MSA\>7 mm2 for distal LM and \>8 mm2 for proximal LM 2. Stent Apposition: No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and \< 1mm length) of the stent over its entire length against the vessel wall 3. Edge Dissection: No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as \>60° of the circumference of the vessel at site of dissection and/or \>2 mm in length of dissection flap)
Target vessel failure
a composite of cardiac death, target-vessel myocardial infarction, clinically-driven target-vessel repeat revascularization, definite or probable stent thrombosis
Time frame: 2 years after last patient enrollment
All-cause death
All-cause death
Time frame: 2 years after last patient enrollment
Cardiac death
Cardiac death
Time frame: 2 years after last patient enrollment
Rate of any myocardial infarction
Any myocardial infarction, defined by Forth Universal definition of myocardial infarction
Time frame: 2 years after last patient enrollment
Rate of spontaneous myocardial infarction
Spontaneous myocardial infarction, defined by Forth Universal definition of myocardial infarction
Time frame: 2 years after last patient enrollment
Rate of procedure-related myocardial infarction
Procedure-related myocardial infarction, defined by ARC II definition
Time frame: 2 years after last patient enrollment
Rate of any revascularization
Any revascularization (clinically-driven or ischemia-driven)
Time frame: 2 years after last patient enrollment
Rate of target vessel revascularization
Target vessel revascularization
Time frame: 2 years after last patient enrollment
Rate of stent thrombosis
Definite or probable stent thrombosis, defined by ARC II definition
Time frame: 2 years after last patient enrollment
Total procedural time
Total procedural time (primary PCI to end of the procedure including amount of staged procedure)
Time frame: at least 1 week after index procedure
Total fluoroscopy time
Total fluoroscopy time (primary PCI to end of the procedure including amount of staged procedure)
Time frame: at least 1 week after index procedure
Total amount of contrast use
Total amount of contrast use (primary PCI to end of the procedure including amount of staged procedure)
Time frame: at least 1 week after index procedure
Incidence of contrast-induced nephropathy
Incidence of contrast-induced nephropathy, defined as an increase in serum creatinine of ≥0.5mg/dL or ≥25% from baseline within 48-72 hours after contrast agent exposure.
Time frame: at least 1 week after index procedure
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After publication of main paper, de-identified data will be shared upon reasonable requests after discussion by Executive Committee.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After publication of main paper.
Access criteria: Executive Committee will discuss to share the de-identified data upon reasonable requests.
Started Mar 2024 (actual). Primary completion is estimated for Mar 2031, 84 months after the start.
Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 84 months is above that.
Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
Chonnam National University Hospital